Next Article in Journal
Genome-Wide Characterization and Expression Analysis of the Germin-Like Protein Family in Rice and Arabidopsis
Next Article in Special Issue
Somatic Genetic Variation in Solid Pseudopapillary Tumor of the Pancreas by Whole Exome Sequencing
Previous Article in Journal
Radiological Patterns of Brain Metastases in Breast Cancer Patients: A Subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry
Open AccessArticle

The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models

1
Institut für Pathologie, Universitätsmedizin Greifswald, 17489 Greifswald, Germany
2
Englander Institut for Precision Medicine, Weill Cornell University of Medicine, New York, NY 10065, USA
3
Pathologisches Institut Diakonie-Krankenhaus, 27356 Rotenburg (Wümme), Germany
4
Institut für Pathologie, Universitätsklinikum Regensburg, 93053 Regensburg, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Terrence Piva
Int. J. Mol. Sci. 2016, 17(10), 1618; https://doi.org/10.3390/ijms17101618
Received: 24 July 2016 / Revised: 27 August 2016 / Accepted: 14 September 2016 / Published: 23 September 2016
(This article belongs to the Special Issue Alterations to Signalling Pathways in Cancer Cells)
Activation of the epidermal growth factor receptor (EGFR) signaling pathway promotes the development of hepatocellular adenoma (HCA) and carcinoma (HCC). The selective EGFR inhibitor Gefitinib was found to prevent hepatocarcinogenesis in rat cirrhotic livers. Thus, Gefitinib might reduce progression of pre-neoplastic liver lesions to HCC. In short- and long-term experiments, administration of N-Nitrosomorpholine (NNM) or intrahepatic transplantation of pancreatic islets in diabetic (PTx), thyroid follicles in thyroidectomized (TTx) and ovarian fragments in ovariectomized (OTx) rats was conducted for the induction of foci of altered hepatocytes (FAH). Gefitinib was administered for two weeks (20 mg/kg) or three and nine months (10 mg/kg). In NNM-treated rats, Gefitinib administration decreased the amount of FAH when compared to controls. The amount of HCA and HCC was decreased, but development was not prevented. Upon all transplantation models, proliferative activity of FAH was lower after administration of Gefitinib in short-term experiments. Nevertheless, the burden of HCA and HCC was not changed in later stages. Thus, EGFR inhibition by Gefitinib diminishes chemical and hormonal also induced hepatocarcinogenesis in the initiation stage in the non-cirrhotic liver. However, progression to malignant hepatocellular tumors was not prevented, indicating only a limited relevance of the EGFR signaling cascade in later stages of hepatocarcinogenesis. View Full-Text
Keywords: hepatocarcinogenesis; intraportal transplantation; epidermal growth factor receptor (EGFR); Gefitinib hepatocarcinogenesis; intraportal transplantation; epidermal growth factor receptor (EGFR); Gefitinib
Show Figures

Figure 1

MDPI and ACS Style

Ribback, S.; Sailer, V.; Böhning, E.; Günther, J.; Merz, J.; Steinmüller, F.; Utpatel, K.; Cigliano, A.; Peters, K.; Pilo, M.G.; Evert, M.; Calvisi, D.F.; Dombrowski, F. The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models. Int. J. Mol. Sci. 2016, 17, 1618. https://doi.org/10.3390/ijms17101618

AMA Style

Ribback S, Sailer V, Böhning E, Günther J, Merz J, Steinmüller F, Utpatel K, Cigliano A, Peters K, Pilo MG, Evert M, Calvisi DF, Dombrowski F. The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models. International Journal of Molecular Sciences. 2016; 17(10):1618. https://doi.org/10.3390/ijms17101618

Chicago/Turabian Style

Ribback, Silvia; Sailer, Verena; Böhning, Enrico; Günther, Julia; Merz, Jaqueline; Steinmüller, Frauke; Utpatel, Kirsten; Cigliano, Antonio; Peters, Kristin; Pilo, Maria G.; Evert, Matthias; Calvisi, Diego F.; Dombrowski, Frank. 2016. "The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models" Int. J. Mol. Sci. 17, no. 10: 1618. https://doi.org/10.3390/ijms17101618

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop